Cuello
Claudio Cuello, Westmount CA
Patent application number | Description | Published |
---|---|---|
20090131277 | PROSTATE CANCER DIAGNOSIS AND TREATMENT - The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. | 05-21-2009 |
20110064654 | PROSTATE CANCER DIAGNOSIS AND TREATMENT - The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. | 03-17-2011 |
20120082618 | PROSTATE CANCER DIAGNOSIS AND TREATMENT - The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. | 04-05-2012 |
Friederike Cuello, London GB
Patent application number | Description | Published |
---|---|---|
20160123994 | AIDING ASSESSMENT OF PROGNOSIS IN INFLAMMATORY DISEASE - Some embodiments are directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein determining the level of octameric PTX3 includes measuring the total amount of PTX3 present, and measuring the amount of octameric PTX3 present, and calculating the proportion of total PTX3 which is present as octamer, wherein if the proportion of octameric PTX3 is greater than 50%, the subject is identified as a likely non-survivor. Some embodiments are also directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein an elevated level of octameric PTX3 compared to a reference level indicates a reduced likelihood of survival. | 05-05-2016 |
Joel L. Cuello, Tucson, AZ US
Patent application number | Description | Published |
---|---|---|
20110287541 | ACCORDION BIOREACTOR - Disclosed herein are bioreactors including a first sheet and a second sheet (one or both of which is substantially transparent to light), wherein the second sheet is disposed adjacent to the first sheet, and the first and second sheets are sealed along a first longitudinal edge, a second longitudinal edge, a first horizontal edge, a second horizontal edge, and at least one intermediate horizontal seal between the first horizontal edge and the second horizontal edge, thereby forming at least two chambers for holding fluid in series along a vertical axis, wherein each of the two or more chambers is oriented at an angle relative to the vertical axis, wherein the angle is about 0° to about 90° and at least one of the chambers is oriented at an angle greater than 0°, and wherein there is at least one opening in each of the first horizontal edge, the second horizontal edge, and intermediate horizontal seal(s); a support structure comprising at least one horizontal support, wherein the horizontal support is located at or near the position of the intermediate horizontal seal; a reservoir below the second horizontal edge of the first and second sheets; and a means for pumping fluid from the reservoir to the first horizontal edge of the first and second sheets. Also disclosed are methods of culturing cells including circulating a suspension of cells in a disclosed bioreactor. In some examples, the cells include microalgae, macroalgae, bacteria, fungi, insect cells, plant cells, animal cells (such as mammalian cells), or plant or animals tissue or organs. In particular examples, the method includes exposing the culture in the bioreactor to a light source (such as sunlight or an artificial light source). | 11-24-2011 |
Maribel Perez Cuello, Ciudad De La Habana CU
Patent application number | Description | Published |
---|---|---|
20110256214 | SINGLE-TIME VACCINES - The invention is related to the field of vaccines. The technical objective is to obtain novel unitemporal therapeutic and prophylactic vaccines (single time vaccination strategy) using simultaneously one or more mucosal doses and one parenteral dose where the use of potent mucosal adjuvants are essential, preferable the Cochleate (AFCo I, Adjuvant Finlay Cochleate 1). The incorporation or co-administration by parenteral and mucosal routes of non-related PL antigens (heterologous), and/or the additional use of delivery systems like Aluminum, Chitosan or oil/water emulsions by parenteral application is also included in this invention. The induction of cellular immune responses than including systemic specific IgG and secretory specific IgA is obtained with at least two simultaneously doses. So, this unitemporal strategy is applicable to obtaining new unique or multiples vaccines (several mucosal vaccine antigens with the corresponding parenteral combine vaccine) in the pharmaceutical industry which permit to increase vaccine coverage and reduce the time-cost of vaccine campaigns. | 10-20-2011 |